

## Jason N. Mock

### Partner

[jmock@foley.com](mailto:jmock@foley.com)

Washington, D.C.  
202.295.4775



Dr. Jason Mock is an intellectual property attorney that helps organizations of all sizes in every facet of the patent life cycle. Whether a client is developing and obtaining new patent rights, managing a complex portfolio, performing due diligence for a transaction, or enforcing or defending its rights, Jason has the experience to guide his clients and serve as a trusted advisor.

Jason's practice spans industries including pharmaceuticals, diagnostics, biotechnology, synthetic biology and biomanufacturing, food science, and agriculture. He has a depth of knowledge to help his clients keep pace in changing environments and realize value from their IP. Jason's clients range from startups and universities to multinational corporations. He is a member of the firm's Chemical, Biotechnology, & Pharmaceutical Practice and the PTAB Trials Practice.

### Presentations and Publications

- J. Mock, T. Yan, and K. Sharon, "IPR proactive defense measures – strategies and considerations for patent owners," *PTAB Trial Insights* (May 2016)
- J. Mock, "Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions," *PTAB Trial Insights* (January 2016)
- Author, "Post-Grant Proceedings at the USPTO and the Rising Tide of Federal Circuit Appeals," *The Federal Circuit Bar Journal* (September 2015)
- Co-author, "The Road Ahead for Kyle Bass's IPRs," *Law360* (August 2015)
- Co-author, "Will New PTAB Rules Impact IPRs Filed by Kyle Bass Hedge Fund?" *The National Law Review* (August 2015)
- Co-author, "Survey of State Laws Against Bad-Faith Patent Assertion," *Bloomberg BNA Patent, Trademark & Copyright Journal* (August 2014)
- Co-author, "Role of the Phospholipase A2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells," *Mol. Pharmaceuticals* (2014)

- Co-author, “Evidence for Distinct Mechanisms of Uptake and Antitumor Activity of Secretory Phospholipase A2 Responsive Liposomes in Prostate Cancer,” *Integr. Biol.* (2012)
- Co-author, “Haloenol Pyranones and Morpholinones as Antineoplastic Agents of Prostate Cancer,” *Bioorg. and Med. Chem. Letters* (2012)
- Co-author, “Secretory Phospholipase A2 Responsive Liposomes,” *J. Pharm. Sci.* (2011)
- Co-author, “Enhanced Antitumor Activity of Low-Dose Continuous Administration Schedules of Topotecan in Prostate Cancer,” *Cancer Bio. and Therapy* (2011)

## Practice Areas

- [Chemical, Biotechnology & Pharmaceutical](#)
- [Protected: Intellectual Property ZH-CN](#)
- [Protected: PTAB Trials ZH-CN](#)

## Education

- The George Washington University Law School (J.D., with honors)
  - Member, *Federal Circuit Bar Journal*
  - George S. Hastings IP Scholar
  - Finnegan Prize for Intellectual Property Law
- University of Georgia (Ph.D., summa cum laude)
  - Pharmaceutical and biomedical science
- University of Georgia (B.S., magna cum laude)
  - Biotechnology, and agricultural and applied economics

## Admissions

- District of Columbia
- Virginia
- U.S. Patent and Trademark Office